Mutation status and immunohistochemical correlation of EGFR mutations in gastrointestinal stromal tumors

1Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23(2): 70-83.Miettinen M Lasota J Gastrointestinal stromal tumors: Pathology and prognosis at different sites Semin Diagn Pathol 2006 23 2 70 8310.1053/j.semdp.2006.09.001Search in Google Scholar

2DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231(1): 51-58.DeMatteo RP Lewis JJ Leung D Mudan SS Woodruff JM Brennan MF Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival Ann Surg 2000 231 1 51 5810.1097/00000658-200001000-00008Search in Google Scholar

3Lv M, Wu C, Zheng Y, Zhao N. Incidence and survival analysis of gastrointestinal stromal tumors in Shanghai: A population-based study from 2001 to 2010. Gastroenterol Res Pract. 2014; 2014: 83416Lv M Wu C Zheng Y Zhao N Incidence and survival analysis of gastrointestinal stromal tumors in Shanghai: A population-based study from 2001 to 2010 Gastroenterol Res Pract 2014 2014 8341610.1155/2014/834136Search in Google Scholar

4Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999; 83(1): 18-29.Pisani P Parkin DM Bray F Ferlay J Estimates of the worldwide mortality from 25 cancers in 1990 Int J Cancer 1999 83 1 18 2910.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-MSearch in Google Scholar

5Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-E386.Ferlay J Soerjomataram I Dikshit R Eser S Mathers C Rebelo M et al Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 2015 136 5 E359 E38610.1002/ijc.29210Search in Google Scholar

6Zhao X, Yue C. Gastrointestinal stromal tumor. J Gastrointest Oncol. 2012; 3(3): 189-208.Zhao X Yue C Gastrointestinal stromal tumor J Gastrointest Oncol 2012 3 3 189 208Search in Google Scholar

7ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23(Suppl 7): vii49-vii55.ESMO/European Sarcoma Network Working Group Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2012 23 Suppl 7 vii49–vii5510.1093/annonc/mds252Search in Google Scholar

8Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demerti G, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000; 156(3): 791-795.Lux ML Rubin BP Biase TL Chen CJ Maclure T Demerti G et al KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors Am J Pathol 2000 156 3 791 79510.1016/S0002-9440(10)64946-2Search in Google Scholar

9Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23): 4342-4349.Heinrich MC Corless CL Demetri GD Blanke CD von Mehren M Joensuu H et al Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 2003 21 23 4342 434910.1200/JCO.2003.04.190Search in Google Scholar

10Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014; 134(11): 2513-2522.Duffy MJ Lamerz R Haglund C Nicolini A Kalousová M Holubec L et al Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update Int J Cancer 2014 134 11 2513 252210.1002/ijc.28384Search in Google Scholar

11Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299(5607): 708-710.Heinrich MC Corless CL Duensing A McGreevey L Chen C-J Joseph N et al PDGFRA activating mutations in gastrointestinal stromal tumors Science 2003 299 5607 708 71010.1126/science.1079666Search in Google Scholar

12Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer. 2008; 8(10): 10.Moutinho C Mateus AR Milanezi F Carneiro F Seruca R Suriano G Epidermal growth factor receptor structural alterations in gastric cancer BMC Cancer 2008 8 10 1010.1186/1471-2407-8-10Search in Google Scholar

13Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003; 2(4): 246-251.Cohen RB Epidermal growth factor receptor as a therapeutic target in colorectal cancer Clin Colorectal Cancer 2003 2 4 246 25110.3816/CCC.2003.n.006Search in Google Scholar

14Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37(Suppl 4): S3-S8.Yarden Y The EGFR family and its ligands in human cancer Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001 37 Suppl 4 S3 S810.1016/S0959-8049(01)00230-1Search in Google Scholar

15Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1997; 8(12): 1197-1206.Voldborg BR Damstrup L Spang-Thomsen M Poulsen HS Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials Ann Oncol 1997 8 12 1197 120610.1023/A:1008209720526Search in Google Scholar

16Yamaoka T, Ohba M, Ohmori T. Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms. Int J Mol Sci. 2017; 18(11): 2420.Yamaoka T Ohba M Ohmori T Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms Int J Mol Sci 2017 18 11 242010.3390/ijms18112420Search in Google Scholar

17Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee CH, Steigen SE, et al. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. 2012; 227(2): 223-233.Edris B Espinosa I Mühlenberg T, Mikels A Lee CH Steigen SE et al ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour J Pathol 2012 227 2 223 23310.1002/path.3986Search in Google Scholar

18Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007; 369(9574): 1731-1741.Rubin BP Heinrich MC Corless CL Gastrointestinal stromal tumour Lancet 2007 369 9574 1731 174110.1016/S0140-6736(07)60780-6Search in Google Scholar

19Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5): 341-354.Hynes NE Lane HA ERBB receptors and cancer: The complexity of targeted inhibitors Nat Rev Cancer 2005 5 5 341 35410.1038/nrc160915864276Search in Google Scholar

20Jiang Z, Li C, Li F, Wang X. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: A systematic review and meta analysis. PLoS One. 2013; 8(2): e56205.Jiang Z Li C Li F Wang X EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: A systematic review and meta analysis PLoS One 2013 8 2 e5620510.1371/journal.pone.0056205357534423441167Search in Google Scholar

21Temel S, Uren D, Yakicier MC. Genetics and molecular basis of gastric cancer. In: Canbay E, Zilberstein B, Sossai P, Jinjuvadia K, Catterjee I, Editors. Overview on Gastric Cancer, 3rd ed. Las Vegas, NV, USA: Open Access eBooks. 2018: 1-13.Temel S Uren D Yakicier MC Genetics and molecular basis of gastric cancer. In: Canbay E, Zilberstein B, Sossai P, Jinjuvadia K, Catterjee I, Editors. Overview on Gastric Cancer, 3rd ed Las Vegas, NV, USA Open Access eBooks 2018 1–13Search in Google Scholar

22Metro G. EGFR targeted therapy for lung cancer: are we almost there? Transl Lung Cancer Res. 2018; 7(Suppl 2): S142-S145.Metro G EGFR targeted therapy for lung cancer: are we almost there? Transl Lung Cancer Res 2018 7 Suppl 2 S142 S14510.21037/tlcr.2018.03.11594323529782570Search in Google Scholar

23Ergin K, Gürsoy E, Başimoǧlu Koca Y, Başaloǧlu H, Seyrek K. Immunohistochemical detection of insulin-like growth factor-I, transforming growth factor-beta2, basic fibroblast growth factor and epidermal growth factor-receptor expression in developing rat ovary. Cytokine. 2008; 43(2): 209-214.Ergin K Gürsoy E Başimoǧlu Koca Y Başaloǧlu H Seyrek K Immunohistochemical detection of insulin-like growth factor-I, transforming growth factor-beta2, basic fibroblast growth factor and epidermal growth factor-receptor expression in developing rat ovary Cytokine 2008 43 2 209 21410.1016/j.cyto.2008.05.01318586513Search in Google Scholar

24Shi S-S, Wu N, He Y, Wei X, Xia Q-Y, Wang X, et al. EFGR gene mutation in gastrointestinal stromal tumors. Histopathology. 2017; 71(4): 553-561.Shi S-S Wu N He Y Wei X Xia Q-Y Wang X et al EFGR gene mutation in gastrointestinal stromal tumors Histopathology 2017 71 4 553 56110.1111/his.1325128485054Search in Google Scholar

25Apicella M, Corso S, Giordano S. Targeted therapies for gastric cancer: Failures and hopes from clinical trials. Oncotarget. 2017; 8(34): 57654-57669.Apicella M Corso S Giordano S Targeted therapies for gastric cancer: Failures and hopes from clinical trials Oncotarget 2017 8 34 57654 5766910.18632/oncotarget.14825559367428915702Search in Google Scholar

26Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517): 202-209.Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma Nature 2014 513 7517 202 20910.1038/nature13480417021925079317Search in Google Scholar

27Huss S, Künstlinger H, Warderlmann E, Kleine MA, Binot E, Merkelbach-Bruse S, et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (pD419del). Mod Pathol. 2013; 26(7): 1004-1012.Huss S Künstlinger H, Warderlmann E Kleine MA Binot E Merkelbach-Bruse S et al A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (pD419del) Mod Pathol 2013 26 7 1004 101210.1038/modpathol.2013.47370129223599150Search in Google Scholar